United States
Choose your country or region:
France
Germany
Italy
Japan
United Kingdom
About
Leadership
Board of Directors
Company History
Corporate Impact and Community Relations
Our Collaborations
Contact Us
Newsroom
News & Stories
Press Releases
Multimedia
Our Tests
Cologuard®
OncoExTra™
Oncoguard® Liver
Oncotype DX®
Oncotype DX Breast DCIS Score®
Oncotype DX Breast Recurrence Score®
Oncotype DX Colon Recurrence Score®
Riskguard™
Pipeline & Data
Breast Radiation Score
Cologuard® 2.0
Colorectal Cancer Blood
LBgard® Blood Tubes
Molecular Residual Disease
Multi-Cancer Early Detection
Clinical Studies
Research
Publications & Abstracts
Exact Academy
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Stock Information
Financial Information
Email Alerts
Contact Us
Join Our Team
×
DIGITAL NEWSROOM
Posts by:
Exact Sciences
August 02, 2022
Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients
July 08, 2022
Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy
June 01, 2022
Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022
May 19, 2022
Exact Sciences at DDW 2022
May 11, 2022
Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX
®
GPS
™
Test, for the First Time in Localized Prostate Cancer Patients
April 28, 2022
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score
®
Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
March 07, 2022
Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer
January 19, 2022
Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients
January 09, 2022
Exact Sciences Announces Preliminary Fourth Quarter 2021 Results
January 09, 2022
Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
January 09, 2022
Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients
December 09, 2021
Exact Sciences Commits $500,000 to Urban League Black Business Hub
1
2
3
4
5
6
7
8
9
...